Kanya Rajangam
CIK 1816676 · Pres. & Chief Med. & Dev. Off. · last filed 2026-03-11
Kanya Rajangam is a Pres. & Chief Med. & Dev. Off. who has filed 15 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing, for SNTI, was dated Mar 11, 2026. Across all open-market trades the lifetime net is −$378.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $140.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$140.2K
3
15
-$378.9K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SNTI | Pres. & Chief Med. & Dev. Off. | 107,843 | $0.96 | $103.6K | -$6.1K | 9 | 2026-03-11 |
| Turnstone Biologics Corp. (TSBX) Delisted | Director | — | $0.35 | — | $0 | 2 | 2024-07-02 |
| NKTX | Chief Medical Officer | 12,800 | $2.86 | $36.6K | -$372.8K | 4 | 2022-01-19 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-11 | SNTI | Tax (F) | −10,757 | $0 | EDGAR |
| 2026-02-03 | SNTI | Tax (F) | −1,384 | $0 | EDGAR |
| 2025-03-11 | SNTI | Conv (C) | +33,000 | $74.2K | EDGAR |
| 2025-03-10 | SNTI | Grant (A) | +78,363 | $0 | EDGAR |
| 2025-02-06 | SNTI | Sell (S) | −1,479 | -$6.1K | EDGAR |
| 2024-12-10 | SNTI | Grant (A) | — | $0 | EDGAR |
| 2024-07-02 | Turnstone Biologics Corp. (TSBX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-02 | SNTI | Grant (A) | +101,000 | $0 | EDGAR |
| 2023-10-17 | Turnstone Biologics Corp. (TSBX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-02-02 | SNTI | Grant (A) | — | $0 | EDGAR |